Fiche centre
University of South Florida
Tampa — United States
Essais liés53clinical trials
VilleTampalocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06106672
Essais cliniques associés
53| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| TAK-935 | Épilepsie | Phase 1/2 | NCT03166215 | Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies | COMPLETED |
| A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications | Parkinson | À vérifier | NCT07330258 | A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications | RECRUITING |
| Prasinezumab | Parkinson | Phase 2 | NCT04777331 | PADOVA — A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease | ACTIVE_NOT_RECRUITING |
| Pitolisant Oral Tablet | Myopathies | Phase 2 | NCT04886518 | Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 | COMPLETED |
| Soticlestat | Épilepsie | Phase 2 | NCT03635073 | Endymion 1 — A Study of Soticlestat in Adults and Children With Rare Epilepsies | TERMINATED |
| Ozanimod | SEP | Phase 3 | NCT06408259 | Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis | RECRUITING |
| T2:C100 | Alzheimer | Phase 2 | NCT05644262 | LiBBY — Life's End Benefits of cannaBidiol and tetrahYdrocannabinol | COMPLETED |
| Ocrelizumab | SEP | À vérifier | NCT02807285 | Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | NO_LONGER_AVAILABLE |
| Interferon beta-1a | SEP | Phase 3 | NCT01247324 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | COMPLETED |
| Atogepant | Migraine | Phase 3 | NCT03777059 | 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine | COMPLETED |
| Atogepant | Migraine | Phase 3 | NCT03939312 | Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine | COMPLETED |
| Galcanezumab | Migraine | Phase 4 | NCT05127486 | CHALLENGE-MIG — A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine | COMPLETED |
| ITI-1284 | Alzheimer | Phase 2 | NCT06540833 | A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease | RECRUITING |
| Solanezumab | Alzheimer | Phase 3 | NCT02008357 | A4 — Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss | COMPLETED |
| AIDP — Automated Imaging Differentiation of Parkinsonism | Parkinson | À vérifier | NCT05913687 | AIDP — Automated Imaging Differentiation of Parkinsonism | ACTIVE_NOT_RECRUITING |
| Deep Brain Stimulation | Parkinson | À vérifier | NCT03664609 | Deep Brain Stimulation (DBS) Retrospective Outcomes Study | RECRUITING |
| Remibrutinib (Blinded) | SEP | Phase 3 | NCT07225504 | REMASTER — A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04544436 | MUSETTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| 23-PPV | SEP | Phase 3 | NCT02545868 | A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis | COMPLETED |
| Edaravone (Radicava®/Radicava ORS®) | Sclérose latérale amyotrophique | À vérifier | NCT04259255 | Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS) | COMPLETED |
| CNP-106 | Myasthénie | Phase 1/2 | NCT06106672 | Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Clevidipine Injection | Hypertension | À vérifier | NCT06402968 | CLUTCH — Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage | RECRUITING |
| AV-1980R 20 µg | Alzheimer | Phase 1 | NCT07158905 | AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980) | RECRUITING |
| COYA 302 | Sclérose latérale amyotrophique | Phase 2/3 | NCT07161999 | ALSTARS — Study of COYA 302 for the Treatment of ALS | RECRUITING |
| Pridopidine | Sclérose latérale amyotrophique | Phase 3 | NCT07322003 | PREVAiLS — Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS | RECRUITING |
| Nipocalimab | Myasthénie | Phase 3 | NCT04951622 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | RECRUITING |
| Efgartigimod IV | Myasthénie | À vérifier | NCT07294170 | ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis | RECRUITING |
| Eptinezumab | Migraine | Phase 3 | NCT05164172 | REJOIN — A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine | RECRUITING |
| Eptinezumab | Migraine | Phase 3 | NCT04965675 | PROSPECT-2 — A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | RECRUITING |
| XEN1101 | Épilepsie | Phase 3 | NCT05667142 | X-ACKT — A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | RECRUITING |
| XEN1101 | Épilepsie | Phase 3 | NCT05718817 | X-TOLE4 — An Open-label Study of XEN1101 in Epilepsy | ENROLLING_BY_INVITATION |
| CT1812 | Alzheimer | Phase 2 | NCT05531656 | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Deep Brain Stimulation (DBS) | Parkinson | À vérifier | NCT02071134 | Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT05269004 | OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ofatumumab approved dose | SEP | Phase 3 | NCT06869785 | FILIOS — Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab | ACTIVE_NOT_RECRUITING |
| Remibrutinib oral treatment | SEP | Phase 3 | NCT06846281 | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | RECRUITING |
| Ocrelizumab IV | SEP | Phase 3 | NCT05232825 | Ocarina II — A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis | COMPLETED |
| RO7121932 IV | SEP | Phase 1 | NCT05704361 | A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Anti-hypertensive therapy | Hypertension | Phase 4 | NCT02299414 | Chronic Hypertension and Pregnancy (CHAP) Project | COMPLETED |
| Ocrelizumab Co-formulated With rHuPH20 | SEP | Phase 1 | NCT07667322 | OCARINA 3 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab Test Formulation | SEP | Phase 2 | NCT07074886 | PORTAMENTO — A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04548999 | GAVOTTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) | ACTIVE_NOT_RECRUITING |
| Interferon beta-1a | SEP | Phase 3 | NCT01412333 | A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis | COMPLETED |
| Efgartigimod IV | Myasthénie | Phase 2 | NCT07284420 | ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod | RECRUITING |
| BIIB100 | Sclérose latérale amyotrophique | Phase 1 | NCT03945279 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis | COMPLETED |
| Pegcetacoplan (APL-2) | Sclérose latérale amyotrophique | Phase 2 | NCT04579666 | MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) | TERMINATED |
| Descartes-08 | Myasthénie | Phase 2 | NCT04146051 | Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | ACTIVE_NOT_RECRUITING |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |
| Ponesimod | SEP | Phase 3 | NCT03232073 | Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis | COMPLETED |
| Fenebrutinib | SEP | Phase 3 | NCT04586023 | FENhance 2 — Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| Fenebrutinib | SEP | Phase 3 | NCT04544449 | FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| IGIV-C | Myasthénie | Phase 2 | NCT02473965 | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis | COMPLETED |